Do men regret prostate biopsy: Results from the PiCTure study by Coyle C et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Coyle C, Morgan E, Drummond FJ, Sharp L, Gavin A. Do men regret prostate 
biopsy: Results from the PiCTure study. BMC Urology 2017, 17, 11. 
Copyright: 
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and 
reproduction in any medium, provided you give appropriate credit to the original author(s) and the 
source, provide a link to the Creative Commons license, and indicate if changes were made. 
DOI link to article: 
http://dx.doi.org/10.1186/s12894-016-0194-y 
Date deposited:   
30/03/2017 
  
RESEARCH ARTICLE Open Access
Do men regret prostate biopsy: Results
from the PiCTure study
Catherine Coyle1*, Eileen Morgan2, Frances J. Drummond3,4, Linda Sharp3,5† and Anna Gavin2†
Abstract
Background: Understanding men’s experience of prostate biopsy is important as the procedure is common,
invasive and carries potential risks. The psychological aspects of prostate biopsy have been somewhat neglected.
The aim of this study was to explore the level of regret experienced by men after prostate biopsy and identify any
associated factors.
Methods: Men attending four clinics in Republic of Ireland and two in Northern Ireland were given a questionnaire
to explore their experience of prostate biopsy. Regret was measured on a Likert scale asking men how much they
agreed with the statement “It [the biopsy] is something I regret.”
Results: Three hundred thirty-five men responded to the survey. The mean age was 63 years (SD ±7 years). Three
quarters of respondents (76%) were married or co-habiting, and (75%) finished education at primary or secondary
school level. For just over two thirds of men (70%) their recent biopsy represented their first ever prostate biopsy.
Approximately one third of men reported a diagnosis of cancer, one third a negative biopsy result, and the remaining
third did not know their result. Two thirds of men reported intermediate or high health anxiety. 5.1% of men agreed or
strongly agreed that they regretted the biopsy.
Conclusions: Level of regret was low overall. Health anxiety was the only significant predictor of regret, with men
with higher anxiety reporting higher levels of regret than men with low anxiety (OR = 3.04, 95% CI 1.58, 5.84).
Men with high health anxiety may especially benefit from careful counselling before and after prostate biopsy.
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Background
Prostate biopsy is an invasive test that involves rectal in-
sertion of an ultrasound probe to diagnose cancer of the
prostate. It is usually prompted by a raised Prostate Spe-
cific Antigen (PSA), prostatic symptoms, an abnormal
digital rectal examination (DRE) or a combination of
these. The incidence of prostate cancer has until recently
increased in most developed countries [1] and has the
potential to increase further in future decades [2]. While
acknowledging that predictions can be uncertain and
that the ongoing debate about the benefits of screening
for prostate cancer may also affect incidence, given
population growth and the growing proportion of older
people in the population, it is possible that the absolute
number of biopsies will increase further. Prostate biopsy
can be difficult for men to tolerate, and commonly re-
sults in physical side effects [3, 4] including bleeding,
pain, urinary retention and infection. While the physical
side effects have been well investigated, the psycho-
logical impact of prostate biopsy has been somewhat
neglected [5, 6].
Decision-related regret is a negative emotion associ-
ated with thinking about a choice one has made or is
about to make [7]. Evidence has grown which shows that
men who choose different treatment options for prostate
cancer report differing levels of regret, and the factors
which predict regret have become a focus of investiga-
tion [8]. Previous studies of men with prostate cancer
suggest that the demographic factors of: older age [8],
being single [8–10] and lower educational attainment
[10, 11] were associated with higher levels of treatment
regret. Clinically, those experiencing treatment-related
complications/side effects [8], with better pre-operative
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erectile function, post-operative incontinence, longer time
from surgery to survey [8], and trait anxiety [9], were
associated with higher levels of treatment regret. Deci-
sional regret with respect to prostate biopsy does not
appear to have been investigated.
The aim of this study was to investigate, for the first
time, levels of decisional regret in men undergoing pros-
tate biopsy and the factors associated with this. The hy-
pothesis was that regret would be low and would not
represent a significant burden for men undergoing pros-
tate biopsy. The rationale for this was that men are likely
to feel reassurance irrespective of the biopsy result; a
negative biopsy result provides relief, and a positive re-
sult justifies the decision to proceed with biopsy.
Methods
Setting
The study took place on the island of Ireland, which com-
prises the Republic of Ireland (RoI) and Northern Ireland
(NI). Four of the eight rapid access clinics (RAC) in the
RoI public healthcare system agreed to take part in the
study. In NI, two of the five Health and Social Care Trusts
which are part of the public-funded NHS participated.
Ethical approval for the study was obtained for the
four participating RoI hospitals and from the office for
Research Ethics in Northern Ireland.
Recruitment
Men were recruited between November 2012 and De-
cember 2013. They were eligible to participate if they were
undergoing prostatic biopsy as a result of a raised PSA
level and/or an abnormal DRE, were over eighteen years
of age, could understand English, were usually resident in
either the RoI or NI, and were deemed well enough by
their medical teams to complete a questionnaire, and in
particular, had no cognitive impairment. They were ineli-
gible if they had a previous diagnosis of prostate cancer.
Two methods of recruitment were used due to differ-
ing ethical and data protection requirements in the par-
ticipating hospitals. In two hospitals in the RoI, a study
information leaflet was sent to all men with their pros-
tate biopsy appointment. Between four and six weeks
post-biopsy these men were sent a questionnaire pack,
with two reminder letters sent to non-responders at fort-
nightly intervals.
In the remaining hospitals all men, when attending for
their prostate biopsy result, were given a questionnaire pack
by nurse specialists. These men received no written re-
minders. In total 811 men were given/sent a questionnaire.
Questionnaire
The questionnaire captured socio-demographic informa-
tion including date of birth, marital status, and educational
attainment.
Men were asked about their urinary symptoms prior
to first PSA test, and also questions about their route to
PSA testing. They were also asked if, prior to biopsy, they
had experienced urinary symptoms or erectile dysfunction.
Information was requested regarding preparation for
biopsy and number of cores taken.
Eighteen statements about men’s feelings about prostate
biopsy (both positive and negative) were developed based
on discussions with prostate cancer survivor groups. Men
were asked to record their level of agreement, on a 4-point
Likert scale ranging from “strongly agree” to “strongly dis-
agree”, with each of the statements. Regret was measured
with the statement “It [the biopsy] is something I regret.”
Information was sought on the biopsy result. Men
were asked questions about their experience of specific
physical side effects following their most recent biopsy
(fever, bleeding, pain, erectile dysfunction and urinary
retention). Questions enquired about the severity, dur-
ation and need for treatment where these occurred.
The questionnaire was pretested with 24 men attending
three prostate cancer groups in the RoI, and modified
accordingly.
A copy of the questionnaire is included as Additional
file 1.
Statistical analysis
As there is limited literature on regret of biopsy, the fac-
tors investigated were chosen based on the literature on
regret after cancer treatment decisions, and are largely
explorative. These included socio-demographic variables,
health anxiety, clinical variables and physical side effects.
Ordinal logistic regression was used to explore rela-
tionships between these variables and regret. An initial
univariate analysis was conducted. Physical side effects
(fever, bleeding, pain, erectile dysfunction and urinary
retention) were analysed as both ‘any side effect’, and
also individually for an association with regret. Variables
significant at p < 0.10 were added simultaneously to a
multivariate model and likelihood ratio tests obtained to
assess whether each variable should be included in the
final model (p ≤ 0.05). The proportional odds assumption
was checked using a likelihood ratio test.
Chi-squared tests were used to investigate differences
in characteristics between those who responded to the
question on regret and those who did not.
Statistical analyses were conducted using STATA re-
lease 11 (StataCorp, College Station, TX).
Results
Three hundred thirty-five men responded to the survey
(response rate 41%). The demographic features of re-
spondents are shown in Table 1. The mean age was
63 years. Three-quarters of respondents (76%) were mar-
ried or co-habiting, and 75% finished education at
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primary or secondary school level. 38% were working
and 39% retired at the time of survey completion. For
just over two thirds (70%) of men, their recent biopsy
represented their first ever biopsy. Approximately one
third of men reported a diagnosis of cancer, one third a
negative biopsy result, and the remaining third did not
know their result. 88% of men reported experiencing
one or more physical side effects, most commonly bleed-
ing (reported by 80%). Just over half (53.4%) of respon-
dents reported that these were the same or better than
expected. Two thirds of men reported high or inter-
mediate health anxiety.
Of the 335 men, 11.9% did not respond to the ques-
tion on regret and thus were excluded from further
analysis. More of the men who completed the regret
question were married or in a partnership (77.9% vs
62.5%, p = 0.03) and had third level education (26.7%
vs. 2.5%, p = 0.01) compared to those who did not.
Of the 295 men who answered the regret question,
5.1% agreed (1.4%) or strongly agreed (3.7%) with the
Table 1 Socio-demographic and clinical characteristics of
participants
Frequency
n (%)
Total 335 (100.0)
Socio-demographic variables
Age at questionnaire completion
< 65 years 192 (57.3)
≥ 65 years 140 (41.8)
Missing 3 (0.9)
Marital status
Married/partnership 254 (75.8)
Other 80 (23.9)
Missing 1 (0.3)
Highest education level completed
Primary/ secondary school 250 (74.6)
Third level 78 (23.3)
Missing 7 (2.1)
Employment status
Working 128 (38.4)
Retired 130 (38.8)
Other 66 (19.7)
Missing 11 (3.3)
Health anxiety
Low 112 (33.4)
Intermediate 148 (44.2)
High 74 (22.1)
Missing 1 (0.3)
Clinical variables
Given choice of first PSA
Yes 243 (72.5)
No 63 (18.8)
Missing 29 (8.7)
Pre-biopsy symptoms
Incontinence
None/mild 244 (72.8)
Moderate/severe 53 (15.8)
Missing 38 (11.3)
Erectile dysfunction
None/mild 239 (71.3)
Moderate/severe 75 (22.4)
Missing 21 (6.3)
Symptoms at time of PSA test
Asymptomatic 188 (56.1)
Symptomatic 119 (35.5)
Other/Missing 28 (8.4)
Table 1 Socio-demographic and clinical characteristics of
participants (Continued)
Enough information pre-biopsy
Yes received enough 270 (80.6)
Yes but would have liked more 25 (7.5)
No but did not want/need any 6 (1.8)
No but would have liked some 13 (3.9)
Missing 21 (6.3)
Biopsy result
Negative 109 (32.5)
Positive 118 (35.2)
Don’t know 108 (32.2)
Expectations of side-effects
Same as expected 117 (34.9)
Worse than expected 46 (13.7)
Not as bad as expected 62 (18.5)
Did not have side-effects 97 (29.0)
Missing 13 (3.9)
Number of previous biopsies (including most recent biopsy)
One 234 (69.9)
More than one 83 (24.8)
Missing 18 (5.4)
Physical Side-effects from biopsy
Any side-effectZa
Yes 295 (88.1)
No 38 (11.3)
Missing 2 (0.6)
aFever, bleeding, pain, erectile dysfunction and urinary retention
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statement “It [the biopsy] is something I regret”. 37.6%
of men disagreed, and 57.3% strongly disagreed.
The univariate analysis found significant associations
between health anxiety (p < 0.01) and number of previ-
ous prostate biopsies (including the most recent biopsy)
(p = 0.03) with regret (Table 2). There was no association
with individual physical side effects and regret, or with
‘any physical side effect’. In multivariate analyses, the
significant association between increasing health anxiety
and biopsy regret remained after adjusting for number
of biopsies. After adjusting for health anxiety, the num-
ber of biopsies was no longer significantly associated
with regret (Table 3).
Discussion
This study found that overall levels of regret were low
(5%) among men following prostate biopsy. A higher
level of regret following prostate cancer treatment deci-
sions (11–12%) has been reported in a number of pub-
lished studies [8, 10, 12] suggesting the possibility of
differences in how men view the decisions around biopsy
and treatment. Further suggestion of the difference be-
tween biopsy and treatment regret is reflected in the dif-
ferent predictor variables significantly associated with
regret in this study compared with the existing literature
on regret following prostate cancer treatment. One theory
to explain this difference and supported by our results is
that these men may have received better pre-procedure
counselling for prostate biopsy. This is based on more
than 80% of men reporting that they received enough in-
formation before the biopsy, and less than one fifth of
men had side effects worse than expected. Also, at this
point more than one-third of these men did not have can-
cer, a fact for which they may be grateful that they had the
biopsy. Further research is needed to clarify if and how
predictors of regret in biopsy and treatment differ with the
aim of ensuring men are appropriately prepared and coun-
selled at each point in the prostate cancer diagnosis and
treatment pathway.
The evidence base for PSA testing as a screening tool
for prostate cancer – the route by which many men are
referred for a prostate biopsy - includes conflicting results
which has not as yet made a clear case for widespread
PSA testing. However its use in Ireland [13] and elsewhere
is widespread. Ransohoff and McNaughton Collins argue
that this widespread use is because the system acts to
make PSA attractive through positive feedback mecha-
nisms [14]. A patient will be grateful for a negative PSA
result or suspicious result followed by a negative biopsy;
furthermore a positive PSA result followed by a cancer
diagnosis makes the patient grateful for early detection.
The clinician is also affected by positive feedback resulting
from PSA testing and subsequent biopsy; we have previ-
ously shown that GPs who detect an asymptomatic
prostate cancer via PSA testing were 3-times more likely
to PSA test other asymptomatic men [15]. Additionally,
litigation will usually only follow a cancer detected too
late, not the one detected too early or which would never
have caused harm.
This theory may explain why the level of regret re-
ported by respondents in this survey was generally low;
a negative biopsy result provides reassurance, and a posi-
tive result provides positive feedback that the test was
worth it as the cancer has been detected.
Health anxiety was the only variable significantly associ-
ated with regret. Health anxiety can be thought of as a con-
tinuum, with hypochondriasis at the extreme. It is
characterised by attentional biases towards illness-related
information and cognitive biases leading to the misinter-
pretation of information as personally threatening and cata-
strophic [16]. Miles et al. [16] examined health anxiety in
the context of screening for colorectal cancer and found
that people with high health anxiety were less reassured fol-
lowing screening. In this study we found that men with
higher health anxiety report higher levels of regret and, fol-
lowing from Miles et al. [16], it may be that men with high
health anxiety were less reassured following prostate biopsy,
and therefore were more likely to regret the procedure.
This study does have some limitations. The question-
naire designed to collect this data was in effect a new in-
strument. However it was tested for face validity and
comprehension with 24 men in the RoI, and available
validated tools were used within the questionnaire such
as the Health Anxiety Questionnaire by Lucock and
Morley, 1996. The limited sample size coupled with the
low level of regret may explain in part why so few vari-
ables were associated with regret. The response rate is
another limitation and we do not have any information
on the characteristics of responders and non-responders,
so we cannot assess participation bias. Respondents who
answered the question on regret were more likely to be
married or in a partnership and to have third level
education than those who did not. The literature cited
previously on regret after treatment decisions indicates
that being married or in a partnership, and higher levels of
educational attainment are associated with lower levels of
regret. This suggests we may have somewhat underesti-
mated regret in the current study.
The major strength of the study is that we were able
to test a wide variety of variables for an association with
regret. The inclusion of men from two jurisdictions with
differing health systems increases generalizability.
The study overall can be viewed as a pilot study into
regret among men following prostate biopsy and associ-
ated factors. This should raise the profile of this issue
among researchers and the health community which
may in turn lead to further research to explore this in
other populations.
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Table 2 Results of univariate ordinal logistic regression testing
for association of predictor variables with regret post-biopsy:
odds ratios (OR) with 95% confidence intervals (CI) and p- values
Frequency Univariate Analysis
n (%) OR (95% CI)a p-value*
Total 295 (100.0)
Socio-demographic variables
Age at questionnaire completion
<65 years 174 (59.0) 1.00
≥65 years 118 (40.0) 0.89 (0.56, 1.42) 0.64
Missing 3 (1.0)
Marital status
Married/ partnership 229 (77..6) 1.00
Other 65 (22.0) 0.99 (0.57, 1.71) 0.96
Missing 1 (0.3)
Highest education level completed
Primary/secondary school 211 (71.5) 1.00
Third level 77 (26.1) 0.67 (0.40, 1.14) 0.14
Missing 7 (2.4)
Employment status
Working 114 (38.6) 1.00
Retired 117 (39.7) 0.72 (0.43, 1.22)
Other 55 (18.6) 1.17 (0.62, 2.19) 0.27
Missing 9 (3.1)
Health anxiety
Low 100 (33.9) 1.00
Intermediate 132 (44.8) 1.80 (1.05, 3.10)
High 63 (21.4) 3.18 (1.68, 6.02) 0.001
Missing 0 (0.0)
Clinical variables
Given choice of first PSA
Yes 215 (72.9) 1.00
No 57 (19.3) 0.86 (0.48, 1.53) 0.60
Missing 23 (7.8)
Pre-biopsy symptoms
Incontinence
None/mild 222 (75.3) 1.00
Moderate/severe 45 (15.3) 1.12 (0.59, 2.11) 0.73
Missing 28 (9.5)
Erectile dysfunction
None/mild 213 (72.2) 1.00
Moderate/ severe 65 (22.0) 1.08 (0.62, 1.89) 0.77
Missing 17 (5.8)
Symptoms at time of PSA test
Asymptomatic 166 (56.3) 1.00
Symptomatic 106 (35.9) 1.34 (0.83, 2.17) 0.23
Other/Missing 23 (7.8)
Table 2 Results of univariate ordinal logistic regression testing
for association of predictor variables with regret post-biopsy:
odds ratios (OR) with 95% confidence intervals (CI) and p- values
(Continued)
Enough information pre-biopsy
Yes received enough 238 (80.7) 1.00
Yes but would have liked
more
24 (8.1) 1.84 (0.81, 4.19)
No but did not want/need
any
5 (1.7) 2.84 (0.47, 17.27)
No but would have liked
some
12 (4.1) 1.10 (0.34, 3.54) 0.36
Missing 16 (5.4)
Biopsy result
Negative 106 (35.9) 1.00
Positive 97 (32.9) 1.45 (0.84, 2.51)
Don’t know 92 (31.2) 1.34 (0.76, 2.35) 0.38
Expectations of side-effects
Same as expected 108 (36..6) 1.00
Worse than expected 41 (13.9) 1.97 (0.98, 3.96)
Not as bad as expected 54 (18.3) 1.39 (0.72, 2.68)
Did not have side-effects 83 (28.1) 1.08 (0.60, 1.93) 0.24
Missing 9 (3.1)
Number of biopsies
One 209 (70.9) 1.00
More than one 72 (24.4) 0.62 (0.36, 1.07) 0.08
Missing 14 (4.8)
Physical Side-effects from biopsy
Any side-effectb
Yes 263 (89.2) 1.00
No 32 (10.9) 0.88 (0.42, 1.84) 0.74
Missing 0 (0.0)
*p-values obtained from the likelihood ratio test
aThe OR for ordinal logistic regression shows the likelihood of having an
increased level of the outcome variable (regret) within each category of the
predictor variable compared to a reference category in the predictor variable
bFever, bleeding, pain, erectile dysfunction and urinary retention
Table 3 Results of multivariate ordinal logistic regression:
multivariate model including predictor variables which had
p-value <0.10 in univariate ordinal logistic regression - odds
ratios (OR) with 95% confidence intervals (CI) and p- values
Variable OR (95% CI) p-values*
Number of previous biopsies (including most recent biopsy)
One 1.00
More than one 0.68 (0.39, 1.19) 0.17
Health anxiety
Low 1.00
Intermediate 1.87 (1.07, 3.26) <0.01
High 3.04 (1.58, 5.84)
*p-values obtained from the likelihood ratio test
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Conclusions
In conclusion, regret is low overall shortly after a pros-
tate biopsy. Men with high health anxiety are more likely
to report higher levels of regret. These men may espe-
cially benefit from careful counselling before and after
biopsy. Given the potential for the number of biopsies
being performed to increase and the limited evidence-
base, further research on different aspects of men’s views
and experiences of biopsy would be of value.
Additional file
Additional file 1: The PiCTure Study – Prostate Investigations in Ireland.
This is a pdf version of the questionnaire used in the Republic of Ireland.
(PDF 1351 kb)
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